Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

MNMD - Mind Medicine Stock Price, Fair Value and News

$9.50-0.26 (-2.66%)
Delayed as of 19 Aug 2025, 11:09 am ET
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

MNMD Price Action

Last 7 days

-2.4%

Last 30 days

9.9%

Last 90 days

28.4%

Trailing 12 Months

53.5%

MNMD Stock Price

MNMD RSI Chart

NovDec2025FebMarAprMayJunJulAug102030405060708090100

MNMD Valuation

Market Cap

742.6M

Price/Earnings (Trailing)

-6.47

Price/Sales (Trailing)

61.92

EV/EBITDA

-12.64

Price/Free Cashflow

-7.31

MNMD Price/Sales (Trailing)

2024AprJulOct2025AprJul20406080100120

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MNMD Fundamentals

MNMD Revenue

Revenue (TTM)

12.0M

Rev. Growth (Yr)

-10.98%

Rev. Growth (Qtr)

14.02%

AprJulOct2024AprJulOct2025Apr6M7M8M9M10M11M12M

MNMD Earnings

Earnings (TTM)

-114.8M

Earnings Growth (Yr)

-630.17%

Earnings Growth (Qtr)

-82.94%

20212022202320242025-120M-100M-80M-60M-40M

MNMD Profitability

EBT Margin

-469.70%

Return on Equity

-61.91%

Return on Assets

-43.3%

Free Cashflow Yield

-13.68%

MNMD Investor Care

Shares Dilution (1Y)

5.47%

Diluted EPS (TTM)

-1.26

Revenue Breakdown

As of: Jun 30, 2025
Total
TotalValuePercent

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
2024AprJulOct2025Apr6M7M8M9M10M11M12M
Net sales
YearQ1Q2Q3Q4
202512.3M12.0M00
20245.9M7.6M9.6M11.6M
20230005.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About Mind Medicine

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.
 CEO
 WEBSITEmindmed.co
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES48

Mind Medicine Frequently Asked Questions

What is the ticker symbol for Mind Medicine? What does MNMD stand for in stocks?

MNMD is the stock ticker symbol of Mind Medicine. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Mind Medicine (MNMD)?

As of Mon Aug 18 2025, market cap of Mind Medicine is 742.62 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MNMD stock?

You can check MNMD's fair value in chart for subscribers.

Is Mind Medicine a good stock to buy?

The fair value guage provides a quick view whether MNMD is over valued or under valued. Whether Mind Medicine is cheap or expensive depends on the assumptions which impact Mind Medicine's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MNMD.

What is Mind Medicine's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Aug 18 2025, MNMD's PE ratio (Price to Earnings) is -6.47 and Price to Sales (PS) ratio is 61.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MNMD PE ratio will change depending on the future growth rate expectations of investors.